Tobira Therapeutics Company Profile (NASDAQ:TBRA)

About Tobira Therapeutics

Tobira Therapeutics logoTobira Therapeutics, Inc., formerly Regado Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company's lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV. The Company's CVC product candidate is an oral, once-daily immunomodulator that blocks the chemokine receptors, CCR2 and CCR5, which are involved in the inflammatory and fibrogenic pathways in NASH and PSC that cause liver damage, and can lead to cirrhosis, liver cancer or liver failure. It is conducting a global Phase IIb study evaluating CVC in NASH patients with liver fibrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TBRA
  • CUSIP:
Key Metrics:
  • Previous Close: $42.09
  • 50 Day Moving Average: $35.35
  • 200 Day Moving Average: $15.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.31
  • P/E Growth: 0.35
  • Market Cap: $N/A
  • Beta: -2.38
Profitability:
  • Return on Equity: -109.45%
  • Return on Assets: -71.32%
Debt:
  • Debt-to-Equity Ratio: 0.44%
  • Current Ratio: 5.38%
  • Quick Ratio: 5.38%
Additional Links:
Companies Related to Tobira Therapeutics:

Analyst Ratings

Consensus Ratings for Tobira Therapeutics (NASDAQ:TBRA) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $86.80 (106.22% upside)

Analysts' Ratings History for Tobira Therapeutics (NASDAQ:TBRA)
Show:
DateFirmActionRatingPrice TargetDetails
10/22/2016Leerink SwannReiterated RatingOutperform$15.00 -> $45.00View Rating Details
9/22/2016MizuhoReiterated RatingBuy$305.00View Rating Details
9/21/2016Cantor FitzgeraldDowngradeBuy -> Hold$19.00 -> $42.00View Rating Details
8/13/2016HC WainwrightReiterated RatingBuy$22.00 -> $31.00View Rating Details
8/10/2016Cowen and CompanyReiterated RatingBuy$11.00View Rating Details
2/22/2015WedbushReiterated RatingUnderperform$1.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Tobira Therapeutics (NASDAQ:TBRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016        
8/9/2016Q216($0.63)($0.71)$1.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.53)($0.65)ViewN/AView Earnings Details
3/3/2016Q415($0.52)($0.50)ViewN/AView Earnings Details
11/10/2015Q315($1.00)($1.22)ViewListenView Earnings Details
8/11/2015Q215($0.99)ViewListenView Earnings Details
11/6/2014Q314($0.45)($0.59)ViewN/AView Earnings Details
8/11/2014Q214($0.51)($0.63)ViewN/AView Earnings Details
5/14/2014Q114($0.62)($1.30)ViewN/AView Earnings Details
11/7/2013($0.43)($1.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tobira Therapeutics (NASDAQ:TBRA)
Current Year EPS Consensus Estimate: $-2.60 EPS
Next Year EPS Consensus Estimate: $-2.18 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.69)($0.69)($0.69)
Q4 20161($0.70)($0.70)($0.70)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tobira Therapeutics (NASDAQ:TBRA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Tobira Therapeutics (NASDAQ:TBRA)
Insider Ownership Percentage: 6.20%
Institutional Ownership Percentage: 62.42%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/31/2016Pentwater Capital Management LMajor ShareholderBuy15,000$41.84$627,600.00View SEC Filing  
10/18/2016Pentwater Capital Management LMajor ShareholderBuy40,000$40.06$1,602,400.00View SEC Filing  
10/17/2016Pentwater Capital Management LMajor ShareholderBuy31,700$40.07$1,270,219.00View SEC Filing  
10/4/2016Pentwater Capital Management LMajor ShareholderBuy4,481$39.83$178,478.23View SEC Filing  
9/29/2016Pentwater Capital Management LMajor ShareholderBuy15,519$39.49$612,845.31View SEC Filing  
9/26/2016Pentwater Capital Management LMajor ShareholderBuy50,000$39.00$1,950,000.00View SEC Filing  
9/23/2016Pentwater Capital Management LMajor ShareholderBuy100,000$39.19$3,919,000.00View SEC Filing  
9/22/2016Pentwater Capital Management LMajor ShareholderBuy1,624,200$39.04$63,408,768.00View SEC Filing  
7/13/2016A/S NovoMajor ShareholderSell59,067$12.02$709,985.34View SEC Filing  
7/7/2016A/S NovoMajor ShareholderSell92,119$12.20$1,123,851.80View SEC Filing  
6/30/2016A/S NovoMajor ShareholderSell66,814$13.04$871,254.56View SEC Filing  
6/6/2016A/S NovoMajor ShareholderSell187,500$10.37$1,944,375.00View SEC Filing  
3/4/2016A/S NovoMajor ShareholderSell190,000$6.80$1,292,000.00View SEC Filing  
11/18/2015A/S Novomajor shareholderSell225,000$9.79$2,202,750.00View SEC Filing  
5/4/2015A/S NovoMajor ShareholderBuy838,041$10.62$8,899,995.42View SEC Filing  
5/4/2015Parters Vii L P DomainMajor ShareholderBuy277,777$10.62$2,949,991.74View SEC Filing  
4/16/2014Robert Kierlinmajor shareholderBuy575,000$6.00$3,450,000.00View SEC Filing  
2/5/2014Robert Kierlinmajor shareholderBuy400,000$5.00$2,000,000.00View SEC Filing  
8/27/2013Raphael WisniewskiDirectorBuy1,215,708$4.00$4,862,832.00View SEC Filing  
8/27/2013Rmi Investments S.A.R.L.Major ShareholderBuy3,866,529$4.00$15,466,116.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Tobira Therapeutics (NASDAQ:TBRA)
DateHeadline
News IconTobira Therapeutics, Inc. (TBRA) Broker Views On Wall Street - NewsDen (NASDAQ:TBRA)
newsden.net - February 17 at 7:11 PM
News IconDeal Spree Continues as Allergan Inks $2.47 Billion Deal for Bay Area Biotech Zeltiq - PharmaLive (press release) (subscription) (NASDAQ:TBRA)
www.pharmalive.com - February 13 at 3:36 PM
News IconSell-side is Weighing in on Tobira Therapeutics, Inc. (NASDAQ:TBRA) Earnings & Targets - Aiken Advocate (NASDAQ:TBRA)
aikenadvocate.com - February 10 at 5:51 AM
News IconWhat are Analysts Expecting for Tobira Therapeutics, Inc. (NASDAQ:TBRA) Earnings? - Aiken Advocate (NASDAQ:TBRA)
aikenadvocate.com - January 27 at 6:07 AM
News IconTobira Therapeutics, Inc. (TBRA) Updated Broker Ratings - NewsDen (NASDAQ:TBRA)
newsden.net - January 22 at 6:25 AM
News IconTobira Therapeutics Inc TBRA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:TBRA)
www.bioportfolio.com - January 21 at 3:03 AM
thestreet.com logoAllergan Hints It Is Ready to Make a Splash for More Near-term Growth (NASDAQ:TBRA)
us.rd.yahoo.com - January 11 at 5:38 AM
News IconTobira Therapeutics Inc TBRA Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:TBRA)
www.bioportfolio.com - January 7 at 5:53 AM
live-pr.com logoTobira Therapeutics, Inc. (TBRA) - Medical Equipment - Deals and Alliances Profile - New Market Study Published (NASDAQ:TBRA)
www.live-pr.com - December 6 at 7:45 PM
insidermonkey.com logoIs Tobira Therapeutics Inc (TBRA) A Good Stock To Buy? - Insider Monkey (blog) (NASDAQ:TBRA)
www.insidermonkey.com - December 6 at 8:15 AM
News IconIs Tobira Therapeutics Inc (TBRA) A Good Stock To Buy? (NASDAQ:TBRA)
feedproxy.google.com - December 5 at 12:18 AM
News IconThis Weeks Target Prices For Tobira Therapeutics, Inc. (TBRA) - NewsDen (NASDAQ:TBRA)
newsden.net - December 3 at 7:05 PM
News IconTobira Therapeutics, Inc. TBRA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:TBRA)
www.bioportfolio.com - November 18 at 11:09 AM
News IconTobira Therapeutics, Inc. TBRA Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:TBRA)
www.bioportfolio.com - November 17 at 12:12 PM
News IconEarnings According to Analysts for Tobira Therapeutics, Inc. (NASDAQ:TBRA)? - CSZ News (NASDAQ:TBRA)
cincysportszone.com - November 10 at 7:47 PM
investors.com logoGilead Cuts Losses On NASH Drug, But Liver Is 'Area Of Opportunity' (NASDAQ:TBRA)
www.investors.com - November 10 at 7:47 PM
News IconWhat is the Street Saying About Tobira Therapeutics, Inc. (NASDAQ:TBRA)? - CSZ News (NASDAQ:TBRA)
cincysportszone.com - November 4 at 7:22 PM
News IconVC Score In Focus for Tobira Therapeutics, Inc. (NASDAQ:TBRA) - StockTalk Daily (NASDAQ:TBRA)
stocktalkdaily.com - November 4 at 11:49 AM
finance.yahoo.com logoBlog Coverage Allergan Completes the $1.69 Billion Acquisition of NASH Therapy Maker (NASDAQ:TBRA)
finance.yahoo.com - November 2 at 11:26 AM
investornewswire.com logoCan Shares Of Tobira Therapeutics, Inc. (NASDAQ:TBRA) Hit $42? - Investor Newswire (NASDAQ:TBRA)
www.investornewswire.com - November 1 at 7:58 PM
News IconUpdate on Valuation Formula's For Tobira Therapeutics, Inc. (NASDAQ:TBRA) - StockTalk Daily (NASDAQ:TBRA)
stocktalkdaily.com - November 1 at 7:58 PM
prnewswire.com logoBiotech Stocks on Investors' Radar -- Agenus, Portola Pharma, Tobira Therapeutics, and Auris Medical - PR Newswire (press release) (NASDAQ:TBRA)
www.prnewswire.com - November 1 at 12:21 PM
biz.yahoo.com logoTOBIRA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisiti (NASDAQ:TBRA)
biz.yahoo.com - November 1 at 12:21 PM
nasdaq.com logoNotable Thursday Option Activity: TBRA, CRUS, BCOR - Nasdaq (NASDAQ:TBRA)
www.nasdaq.com - October 28 at 11:39 AM
nasdaq.com logoNotable Thursday Option Activity: TBRA, CRUS, BCOR (NASDAQ:TBRA)
www.nasdaq.com - October 27 at 7:46 PM
wsj.com logoAllergan CEO Brent Saunders Succeeds Paul Bisaro as Chairman (NASDAQ:TBRA)
www.wsj.com - October 26 at 7:37 PM
investornewswire.com logoTobira Therapeutics, Inc. (NASDAQ:TBRA) Buy Calls At 0 - Investor Newswire (NASDAQ:TBRA)
www.investornewswire.com - October 25 at 7:42 PM
insidermonkey.com logoHedge Funds Are Cashing Out Of These Stocks As Investors Yank Capital (NASDAQ:TBRA)
www.insidermonkey.com - October 25 at 10:26 AM
finance.yahoo.com logoAllergan's Nocturia Drug Gets FDA Advisory Committee's Nod (NASDAQ:TBRA)
finance.yahoo.com - October 21 at 11:13 AM
streetinsider.com logoTobira Therapeutics (TBRA) Presents Phase 2b CENTAUR Year 1 Analysis at AASLD Annual Meeting (NASDAQ:TBRA)
www.streetinsider.com - October 20 at 7:55 PM
benzinga.com logoTobira Therapeutics Announces Late-Breaking Oral... (NASDAQ:TBRA)
www.benzinga.com - October 20 at 12:45 PM
finance.yahoo.com logoTobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting (NASDAQ:TBRA)
finance.yahoo.com - October 20 at 12:45 PM
finance.yahoo.com logo10:48 am Tobira Therapeutics announces a late-breaking oral presentation of Centaur Phase 2b trial results will be presented at the American Academy for the Study of Liver Diseases Annual Meeting (NASDAQ:TBRA)
finance.yahoo.com - October 20 at 12:45 PM
streetinsider.com logoAllergan (AGN) Announces Early HSR Act Termination in Proposed Merger with Tobira (NASDAQ:TBRA)
www.streetinsider.com - October 19 at 7:13 PM
marketnewsvideo.com logoNotable Wednesday Option Activity: PCLN, TBRA, CFX (NASDAQ:TBRA)
www.marketnewsvideo.com - October 19 at 7:13 PM
nasdaq.com logoFTC Grants Early Termination Of HSR Waiting Period For Allergan-Tobira Deal (NASDAQ:TBRA)
www.nasdaq.com - October 19 at 10:50 AM
finance.yahoo.com logoAllergan (AGN) Brings Juvederm Voluma XC to U.S. Market (NASDAQ:TBRA)
finance.yahoo.com - October 19 at 10:50 AM
News IconEarnings According to Analysts for Tobira Therapeutics, Inc ... - CSZ News (NASDAQ:TBRA)
cincysportszone.com - October 14 at 10:54 AM
thestreet.com logoControversy Over Allergan's 500% Premium for Tobira Looks Overdone (NASDAQ:TBRA)
www.thestreet.com - October 12 at 7:35 PM
News IconInvestor News: Buyout of Tobira Therapeutics Inc (NASDAQ:TBRA) under Investigation - GroundReport (NASDAQ:TBRA)
www.groundreport.com - October 4 at 7:05 PM
investornewswire.com logoTobira Therapeutics, Inc. (NASDAQ:TBRA) Sell Recommendations At 0 - Investor Newswire (NASDAQ:TBRA)
www.investornewswire.com - October 4 at 7:05 PM
News IconInvestor News: Buyout of Tobira Therapeutics Inc (NASDAQ:TBRA) under Investigation (NASDAQ:TBRA)
www.groundreport.com - October 3 at 11:25 AM
finance.yahoo.com logoTobira Therapeutics Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting (NASDAQ:TBRA)
finance.yahoo.com - October 3 at 11:25 AM
finance.yahoo.com logo6 Best Performing Drug Stocks of September (NASDAQ:TBRA)
finance.yahoo.com - October 3 at 11:25 AM
finance.yahoo.com logoBotox-maker Allergan just struck another billion-dollar deal (NASDAQ:TBRA)
finance.yahoo.com - October 3 at 11:25 AM

Social

What is Tobira Therapeutics' stock symbol?

Tobira Therapeutics trades on the NASDAQ under the ticker symbol "TBRA."

Where is Tobira Therapeutics' stock going? Where will Tobira Therapeutics' stock price be in 2017?

5 equities research analysts have issued 1 year target prices for Tobira Therapeutics' shares. Their predictions range from $11.00 to $305.00. On average, they expect Tobira Therapeutics' share price to reach $86.80 in the next twelve months.

When will Tobira Therapeutics announce their earnings?

Tobira Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 8th 2016.

What are analysts saying about Tobira Therapeutics stock?

Here are some recent quotes from research analysts about Tobira Therapeutics stock:

  • According to Zacks Investment Research, "Tobira Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to treat liver disease, inflammation, liver fibrosis and human immunodeficiency virus. Tobira Therapeutics, Inc., formerly known as Regado Biosciences, Inc., is headquartered in San Francisco, CA. " (10/20/2016)

  • Cowen and Company analysts commented, "TBRA’s CVC Ph2 CENTAUR trial recently missed the primary endpoint (NAS reduction)." (8/10/2016)

How do I buy Tobira Therapeutics stock?

Shares of Tobira Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Tobira Therapeutics stock cost?

One share of Tobira Therapeutics stock can currently be purchased for approximately $42.09.

Tobira Therapeutics (NASDAQ:TBRA) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Tobira Therapeutics (NASDAQ:TBRA)

Earnings History Chart

Earnings by Quarter for Tobira Therapeutics (NASDAQ:TBRA)

Dividend History Chart

Dividend Payments by Quarter for Tobira Therapeutics (NASDAQ:TBRA)

Last Updated on 2/19/2017 by MarketBeat.com Staff